Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 16/20 | 0.44 |
| ▸ | HTR2B | P41595 | 15/20 | 0.44 |
| ▸ | HTR2A | P28223 | 7/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 3/20 | 0.38 |
| ▸ | NOS2 | P35228 | 3/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5596782 | 0.93 | HTR2C (0.43) | HTR2CHTR2BHTR2ADRD2NOS1 | |
| SCHEMBL5415547 | 0.93 | HTR2C (0.44) | HTR2CHTR2BHTR2ADRD2NOS1 | |
| SCHEMBL5418105 | 0.86 | HTR2C (0.44) | HTR2CHTR2BHTR2ADRD2NOS1 | |
| SCHEMBL5596727 | 0.81 | SCN9A (0.39) | HTR2CHTR2B | |
| SCHEMBL5596820 | 0.81 | OPRM1 (0.34) | DRD2 | |
| SCHEMBL5596798 | 0.81 | HTR2C (0.46) | HTR2CHTR2BHTR2ADRD2NOS1 | |
| SCHEMBL5596967 | 0.80 | HTR2C (0.43) | HTR2CHTR2BHTR2ADRD2NOS1 | |
| SCHEMBL5596602 | 0.80 | HTR2C (0.43) | HTR2CHTR2BHTR2ADRD2NOS1 | |
| SCHEMBL5597033 | 0.80 | HTR2C (0.44) | HTR2CHTR2BHTR2A | |
| SCHEMBL5418022 | 0.79 | HTR2C (0.44) | HTR2CHTR2BHTR2ADRD2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1829876-A1 | NITROGENEOUS TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | MYO1B, CHRM1, MYL12A | HTR2C 1430/4885HTR2B 1795/4885HTR2A 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.